Shares of The Cooper Cos. (NYSE:COO) gapped up before the market opened on Tuesday . The stock had previously closed at $183.92, but opened at $184.19. The Cooper Cos. shares last traded at $185.56, with a volume of 211,199 shares trading hands.

Several analysts have commented on the stock. Piper Jaffray Cos. reiterated a “buy” rating on shares of The Cooper Cos. in a research report on Saturday, June 4th. Stephens reiterated a “hold” rating on shares of The Cooper Cos. in a research report on Saturday, June 4th. Jefferies Group reiterated a “buy” rating and set a $190.00 target price (up previously from $175.00) on shares of The Cooper Cos. in a research report on Thursday, June 2nd. Zacks Investment Research cut shares of The Cooper Cos. from a “buy” rating to a “hold” rating in a research report on Friday, August 5th. Finally, Robert W. Baird reiterated an “outperform” rating and set a $185.00 target price on shares of The Cooper Cos. in a research report on Saturday, June 25th. Four analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $170.10.

The firm has a market capitalization of $8.91 billion and a P/E ratio of 43.50. The company has a 50-day moving average price of $180.59 and a 200-day moving average price of $161.50.

The Cooper Cos. (NYSE:COO) last issued its quarterly earnings results on Thursday, June 2nd. The medical device company reported $2.05 EPS for the quarter, topping analysts’ consensus estimates of $1.91 by $0.14. During the same quarter in the previous year, the business posted $1.72 EPS. The business had revenue of $484.80 million for the quarter. The business’s revenue for the quarter was up 11.5% compared to the same quarter last year. Analysts anticipate that The Cooper Cos. will post $8.42 earnings per share for the current year.

The firm also recently declared a semiannual dividend, which was paid on Friday, August 5th. Stockholders of record on Friday, July 22nd were issued a dividend of $0.03 per share. The ex-dividend date of this dividend was Wednesday, July 20th. This represents a dividend yield of 0.03%.

In related news, Director Allan E. Rubenstein sold 3,000 shares of The Cooper Cos. stock in a transaction on Monday, June 6th. The shares were sold at an average price of $165.01, for a total transaction of $495,030.00. Following the completion of the transaction, the director now owns 11,039 shares of the company’s stock, valued at $1,821,545.39. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Michael Kalkstein sold 1,000 shares of The Cooper Cos. stock in a transaction on Friday, July 8th. The stock was sold at an average price of $178.55, for a total transaction of $178,550.00. Following the transaction, the director now directly owns 14,215 shares of the company’s stock, valued at approximately $2,538,088.25. The disclosure for this sale can be found here.

A number of institutional investors have recently made changes to their positions in COO. Principal Financial Group Inc. increased its position in shares of The Cooper Cos. by 2.7% in the fourth quarter. Principal Financial Group Inc. now owns 154,051 shares of the medical device company’s stock worth $20,674,000 after buying an additional 4,043 shares in the last quarter. Schroder Investment Management Group increased its position in shares of The Cooper Cos. by 13.1% in the fourth quarter. Schroder Investment Management Group now owns 307,100 shares of the medical device company’s stock worth $41,213,000 after buying an additional 35,600 shares in the last quarter. Finally, I.G. Investment Management LTD. increased its position in shares of The Cooper Cos. by 40.6% in the fourth quarter. I.G. Investment Management LTD. now owns 30,760 shares of the medical device company’s stock worth $4,128,000 after buying an additional 8,884 shares in the last quarter.

The Cooper Companies, Inc (Cooper) is a medical device company. The Company operates through two business units: CooperVision, Inc (CooperVision) and CooperSurgical, Inc (CooperSurgical). CooperVision develops, manufactures and markets a range of soft contact lenses for the vision correction market. CooperVision offers Biofinity monthly spherical, toric and multifocal lenses under the Avaira brand.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.